These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 27107268

  • 1. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S.
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
    Wilmot HV, Hogwood J, Gray E.
    Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial.
    Escuriola Ettingshausen C, Hegemann I, Simpson ML, Cuker A, Kulkarni R, Pruthi RK, Garly ML, Meldgaard RM, Persson P, Klamroth R.
    Res Pract Thromb Haemost; 2019 Apr; 3(2):268-276. PubMed ID: 31011711
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Underestimation of N-glycoPEGylated factor IX one-stage clotting activity owing to contact activator-impaired activation.
    Persson E, La Cour Christoffersen C.
    Res Pract Thromb Haemost; 2017 Oct; 1(2):259-263. PubMed ID: 30046695
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
    Nummi V, Jouppila A, Lassila R.
    Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
    [Abstract] [Full Text] [Related]

  • 18. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
    Sommer JM, Sadeghi-Khomami A, Barnowski C, Wikén M, Willemze AJ.
    Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
    Gray E, Hogwood J, Dougall T, Rigsby P, Matejtschuk P, Terao E.
    Pharmeur Bio Sci Notes; 2021 Jun; 2021():26-68. PubMed ID: 33783349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.